Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1682
Shown on this page
12
Current sort
Recently updated
Campus scope
Memorial Sloan Kettering Cancer Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Memorial Sloan Kettering Cancer Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 697–708 of 1,682 matching trials with a site at Memorial Sloan Kettering Cancer Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

NCT05130801
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer
Interventions
pHLIP® ICG NIRF imaging
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Montvale, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976
Site status not listed — check the official record
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Epcoritamab, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years to 79 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
68
States / cities
Tucson, Arizona • Yuma, Arizona • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810
Site status not listed — check the official record
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma
Interventions
Epcoritamab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
70
States / cities
Mobile, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Recruiting Phase 1 Interventional

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

NCT05365581
Status at this site: Recruiting
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil, Ramucirumab, Paclitaxel, Irinotecan, Capecitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
13
States / cities
Orange, California • Santa Monica, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Active, not recruiting Phase 2 Interventional Results available

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC

NCT02259621
Site status not listed — check the official record
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Carboplatin, Paclitaxel, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • New York, New York • Edmonds, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Active, not recruiting Phase 1 Interventional

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

NCT05552469
Site status not listed — check the official record
View directory record Official record
Conditions
Myeloid Diseases
Interventions
DFV890
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Stanford, California • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Recruiting Phase 1 Interventional

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

NCT03647358
Status at this site: Recruiting
View directory record Official record
Conditions
Thyroid Carcinoma, Metastatic Thyroid Carcinoma
Interventions
PET/CT Scan, Iodine-124
Device · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Recruiting Phase 1Phase 2 Interventional

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

NCT03104491
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
Inotuzumab Ozogamicin
Drug
Lead sponsor
Leland Metheny
Other
Eligibility
16 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Westwood, Kansas • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Active, not recruiting Not applicable Interventional

A Study of the BREAST-Q REACT Tool for People Having Breast Surgery

NCT06550401
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Conserving Surgery, Mastectomy With Reconstruction
Interventions
BREAST-Q Physical Well-Being, QuickDASH
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Recruiting Phase 2 Interventional

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

NCT05570253
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, Metastatic Triple-Negative Breast Cancer
Interventions
Eribulin, SDX-7320, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Recruiting Phase 1 Interventional

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

NCT06597721
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor, PDAC, HNSCC
Interventions
ADCE-T02
Drug
Lead sponsor
Adcendo ApS
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Rogers, Arkansas • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 5, 2026, 1:41 PM EST
Active, not recruiting Phase 2 Interventional

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326
Site status not listed — check the official record
View directory record Official record
Conditions
Adenocarcinoma, Pancreatic Ductal
Interventions
Autogene cevumeran, Atezolizumab, mFOLFIRINOX
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
30
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 5, 2026, 1:41 PM EST

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Memorial Sloan Kettering Cancer Center at any site, browse by condition, or browse by U.S. city.